Company: AZN
Filing Date: 2025-09-29
Form Type: 6-K
Source: 0001104659-25-094039
Chunk: 39

Company: ASTRAZENECA PLC
Filing Date: 2025-09-29
Form: 6-K
Chunk 39
---
) and do all such other things and execute and deliver all such documents as may in the opinion of the Company or attorney or agent, be necessary or desirable to give effect to the arrangements in Article 149 (including effecting the transfer of AstraZeneca Shares to the DR Depositary Nominee (as nominee for the DR Depositary) prior to the onward inter-systems transfer from the DR Depositary Nominee to the DTC Nominee. | ​ | ​ |

27

TABLE OF CONTENTS

PART VI
DEFINITIONS The definitions set out below apply throughout this document, unless the context requires otherwise.

| ​ | “ADR Depositary”          | ​ | ​ | JPMorgan Chase Bank, N.A., in its capacity as depositary for the AstraZeneca ADSs representing AstraZeneca Shares under the AstraZeneca ADR facility;                                                                                                                                                                                                                                  | ​ |
| ​ | “ADR Programme”           | ​ | ​ | the American Depositary Receipts programme operated pursuant to the terms of the Second Amended and Restated Deposit Agreement dated as of 6 February 2025, by and among (i) the Company (ii) the ADR Depositary and (iii) all registered holders and beneficial owners of AstraZeneca ADSs evidenced by AstraZeneca ADRs issued thereunder;                                           | ​ |
| ​ | “Affiliate Shareholder”   | ​ | ​ | any person who holds Affiliate Shares (and Affiliate Shareholders will be notified of their designation as such);                                                                                                                                                                                                                                                                      | ​ |
| ​ | “Affiliate Shares”        | ​ | ​ | AstraZeneca Shares held by any Affiliate Shareholder immediately prior to the Effective Time (including AstraZeneca Shares represented by AstraZeneca ADSs immediately prior to the effectiveness of the Harmonised Listing Structure) which are, or are identified by the Company to CTCNA as to be treated as, restricted securities for the purposes of US federal securities laws; | ​ |
| ​ | “AstraZeneca”or“Company”  | ​ | ​ | AstraZeneca PLC, a company limited by shares and incorporated in the United Kingdom with registered number 02723534;                                                                                                                                                                                                                                                                   | ​ |
| ​ | “AstraZeneca ADRs”        | ​ | ​ | has the meaning given to it in paragraph 1 (Overview of existing arrangements in respect of AstraZeneca’s listed securities) of Part III (Settlement and